Clinical trials: Muscle-Invasive Bladder Carcinoma
Bladder Cancer
Study of Tumour Focused Radiotherapy for Bladder Cancer
Bladder cancer is the seventh most common cancer in the UK, with 10,399 new cases diagnosed in 2011. In a quarter of these cases the cancer has infiltrated the muscular wall of the bladder (muscle invasive) and is life…
- Trial name
- RAIDER (NCT02447549)
- Testing
- WBRT, SART, DART
- Where
- 49 sites in Australia, New Zealand and 1 more
- Volunteers
- 345 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Carcinoma, Transitional Cell, Bladder Neoplasms
Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure
The main purpose of this research study is to evaluate the safety and dosing of CG0070.
- Trial name
- NCT00109655
- Testing
- Oncolytic adenovirus (serotype 5) - CG0070
- Where
- 10 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- Cell Genesys
Urinary Bladder Neoplasms
Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer
Nowadays, Immune Checkpoint Inhibitor (ICI) has become one of the new drugs for the treatment of advanced uroepithelial carcinoma.
- Trial name
- CBPTMI (NCT05445648)
- Testing
- Tislelizumab Injection, Transurethral resection of bladder tumor, Adjuvant radiotherapy
- Where
- China
- Volunteers
- 65 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Transurethral Resection of Bladder Tumor
Evaluation of the Role of Early Second Look TURBT in Management of High Risk Non Muscle Invasive Bladder Cancer
The aim is to evaluate the intraoperative, postoperative and pathologic findings of early second look TURBT and the factors affecting these findings to assess the value of early second TURBT in the management of high risk NMIBC.
- Trial name
- NCT07642102
- Testing
- early second look transurethral resection of bladder tumor
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Ain Shams University
Bladder Cancer
Thulium Fiber Laser En-bloc Resection vs Conventional Transurethral Resection of Non-muscle-invasive Bladder Cancer
Ongoing efforts aim at overcoming the challenges of conventional transurethral resection of bladder tumor (TURBT) such as the high recurrence rate, difficulty of pathologic interpretation and complications including wall injury.
- Trial name
- NCT04110483
- Testing
- Thulium fiber laser en-bloc resection of non-muscle-invasive bladder cancer, Transurethral resection of non-muscle-invasive bladder cancer
- Where
- Russia
- Volunteers
- 130 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Non Muscle Invasive Bladder Cancer
Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin
To evaluate the activity of intravesical administration of CG0070 and intravenous administration of Pembrolizumab in patients with tissue pathology-confirmed non-muscle invasive bladder cancer (NMIBC) who have…
- Trial name
- CORE-001 (NCT04387461)
- Testing
- CG0070, Pembrolizumab Injection, n-dodecyl-B-D-maltoside
- Where
- 19 sites in United States, South Korea
- Volunteers
- 35 people
- Sponsor
- CG Oncology, Inc.
Non Muscle-invasive Bladder Cancer
Evaluation of Immediate Preoperative Instillation (IPOI) of Mitomycin C Compared to Early Postoperative Instillation (IPOP) in Non-muscle Invasive Bladder Cancer
This study seeks to optimize the management of TVNIM (reduction of the risk of reccurence of the disease) by comparing in terms of efficacy and tolerance the immediate preoperative administration of mitomycin C (IPOI) to an early…
- Trial name
- NCT02075060
- Testing
- IPOI, IPOP
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- Poitiers University Hospital
Urinary Bladder Neoplasms, BCG Vaccine
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Previous studies have reported the efficacy of Bacillus Calmette-Guérin (BCG) combined with other drugs for the treatment of bladder cancer.
- Conditions
- Urinary Bladder Neoplasms, BCG Vaccine, Immunotherapy, Active, Multicenter Study
- Trial name
- NCT06441110
- Testing
- Tislelizumab in Combination with Bacillus Calmette-Guérin
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Fujian Medical University Union Hospital
Bladder Cancer
Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder
ABACUS is an open-label, international, multi-centre, window of opportunity phase II trial for patients with histologically confirmed (T2-T4a) transitional cell carcinoma of the bladder.
- Trial name
- ABACUS (NCT02662309)
- Testing
- MPDL3280A
- Where
- 20 sites in France, Netherlands and 2 more
- Volunteers
- 96 people
- Sponsor
- Queen Mary University of London
Bladder Cancer
Positron Emission Tomography (PET) Study for Staging of Muscle Invasive Bladder Cancer
This prospective pilot study will enroll 30 patients with cT2/T3-N0-M0 urothelial carcinoma of the bladder for whom radical cystectomy with pelvic lymph node dissection is planned.
- Trial name
- NCT01655745
- Testing
- FDG PET/MR
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-muscle Invasive Bladder Cancer
Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer
A study to validate, in a prospective manner, the ability of the predefined Genomic Health bladder cancer assay to detect recurrence in patients undergoing surveillance for non-muscle invasive bladder cancer.
- Trial name
- NCT02969109
- Where
- United States
- Volunteers
- 417 people
- Sponsor
- Genomic Health®, Inc.
Bladder Carcinoma
Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection
The primary objective of the study is to assess the bladder cancer recurrence free rate, according to a phase II pilot study, of intravesical instillation of sequential BCG and EMDA/MMC after TUR.
- Trial name
- NCT02202044
- Testing
- Intravesical BCG and EMDA/MMC
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- University of Colorado, Denver
Muscle Invasive Bladder Cancer (MIBC)
Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC
The goal of this clinical trial is to learn if oral probiotics (Clostridium butyricum) work to improve the efficacy of targeted therapy plus immunotherapy in bladder preservation setting for cisplatin-ineligible T2-3N0M0 bladder…
- Trial name
- NCT07474064
- Testing
- Probiotic, Disitamab Vedotin, Toripalimab
- Where
- China
- Volunteers
- 146 people
- Sponsor
- chenxu
Bladder Cancer
A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)
This is a randomized, multicenter, two-arm, double-blind, placebo-controlled study of Qapzola in participants with low- to intermediate-risk non-muscle invasive bladder cancer (NMIBC), assessed according to the 2016 American…
- Trial name
- NCT03224182
- Testing
- Qapzola
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Bladder (Urothelial, Transitional Cell) Cancer, NMIBC
DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC
The purpose of this study is to learn about the safety and effects of the study medicine (Disitamab Vedotin) in people with non-muscle invasive bladder cancer.
- Trial name
- HERO (NCT07207824)
- Testing
- Active Comparator: BCG induction and maintenance, DV + BCG induction and maintenance
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Fudan University
Muscle Invasive Bladder Carcinoma, Localized Cancer
Pembrolizumab in Muscle-invasive Bladder Cancer
Subjects with cT2-T3N0M0 urothelial cancer of the bladder will be enrolled. After completing two cycles of pembrolizumab, subjects will undergo a restaging MRI of the abdomen and pelvis with a standard acquisition protocol (as…
- Conditions
- Muscle Invasive Bladder Carcinoma, Localized Cancer, Urothelial Carcinoma
- Trial name
- NCT05406713
- Testing
- Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Matthew Galsky
Bladder Cancer
Investigating Bladder Chemotherapy Instead of Surgery for Low Risk Bladder Cancer
Patients diagnosed with low risk non-muscle invasive bladder cancer (NMIBC) are at risk of frequent low grade recurrence, which usually necessitates surgical intervention under general anaesthetic.
- Trial name
- CALIBER (NCT02070120)
- Testing
- Mitomycin C, Surgical Management
- Where
- 38 sites in United Kingdom
- Volunteers
- 82 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Bladder (Urothelial, Transitional Cell) Cancer
Phase II Prospective Cohort Study of Intravesical Recombinant Human Type 5 Adenovirus Injection for Treatment of High-Risk Non-Muscle Invasive Bladder Cancer: Evaluating Efficacy and Safety
This is a prospective, open label, single center clinical study on the use of recombinant human adenovirus type 5 injection for bladder instillation therapy in high-risk non muscle invasive bladder urothelial carcinoma patients.
- Trial name
- REBIRTH-013 (NCT07356791)
- Testing
- Recombinant Human Adenovirus Type 5 injection
- Volunteers
- 18 people
- Sponsor
- RenJi Hospital
Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy
This is a Phase 3, open-label single-arm trial designed to evaluate the safety and efficacy of NDV-01 (sustained-release gemcitabine-docetaxel) in adult participants with NMIBC with CIS who have failed BCG therapy and who have…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
- Trial name
- RESCUE (NCT07342517)
- Testing
- NDV-01 (sustained-release gemcitabine-docetaxel)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Relmada Therapeutics, Inc.
Non-Muscle Invasive Bladder Cancer
Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 Study
Standard treatment for patients with high-risk NMIBC (high-grade Ta, CIS, or any T1) consists of intravesical Bacillus Calmette-Guerin (BCG) immunotherapy.
- Trial name
- BRACE (NCT06990061)
- Testing
- Radiation therapy
- Where
- 3 sites in Belgium
- Volunteers
- 50 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC